No, it makes no sense to use Symbicort alongside another inhaler containing the same steroid or long-acting β-agonist for post-viral cough.
Using Symbicort (budesonide/formoterol) with another inhaler containing duplicate components is contraindicated and potentially dangerous. The FDA label explicitly warns that patients using Symbicort should not use an additional long-acting β-agonist (LABA) for any reason, as this can lead to overdose, clinically significant cardiovascular effects, and fatalities 1.
Why This Is Problematic
Duplication of Long-Acting β-Agonists
- The FDA specifically prohibits concurrent LABA use: "Patients using SYMBICORT should not use an additional LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate) for any reason" 1
- LABAs carry a black box warning for increased asthma-related deaths when used as monotherapy, and excessive use increases cardiovascular risks 1
- Formoterol is already present in Symbicort at therapeutic doses; adding another LABA creates unnecessary and dangerous duplication
Duplication of Inhaled Corticosteroids
- Using two inhalers with the same steroid (budesonide) provides no additional benefit and increases the risk of:
- Oral candidiasis
- Systemic corticosteroid effects
- Immunosuppression 1
Appropriate Treatment for Post-Viral Cough
The ACCP guidelines provide a clear treatment algorithm for post-infectious cough 2:
First-Line Approach
- Inhaled ipratropium should be tried first, as it may attenuate the cough (Grade B evidence) 2
Second-Line Approach
- Inhaled corticosteroids alone (like budesonide) should be considered when cough persists despite ipratropium and adversely affects quality of life (Grade E/B) 2
- Note: The guidelines recommend inhaled corticosteroids, not combination ICS/LABA therapy
For Severe Cases
- Short course of oral prednisone (30-40 mg daily) when other causes are ruled out (Grade C) 2
- Central antitussives (codeine, dextromethorphan) when other measures fail 2
Key Clinical Pitfalls
The guidelines do not recommend combination ICS/LABA therapy for simple post-viral cough. Symbicort is indicated for asthma and COPD, not post-infectious cough 1. If a patient has developed post-viral bronchial hyperresponsiveness mimicking asthma, then Symbicort alone might be appropriate—but never with a second similar inhaler.
If the patient is already on Symbicort and needs additional therapy for persistent post-viral cough, appropriate options include:
- Adding ipratropium (different mechanism)
- Adding a short-acting β-agonist for rescue (albuterol/salbutamol)—not another LABA
- Considering oral corticosteroids for severe cases
- Adding antitussive agents
Bottom line: One inhaler with budesonide/formoterol is sufficient. Adding another inhaler with overlapping components violates FDA safety warnings and provides no therapeutic benefit.